Immix Biopharma’s (IMMX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a research report report published on Monday,Benzinga reports. They currently have a $7.00 price target on the stock.

Immix Biopharma Stock Up 1.0 %

NASDAQ:IMMX opened at $1.99 on Monday. The business’s 50-day simple moving average is $2.14 and its two-hundred day simple moving average is $1.93. Immix Biopharma has a 52 week low of $1.26 and a 52 week high of $3.80. The stock has a market cap of $54.74 million, a PE ratio of -2.34 and a beta of 0.24.

Immix Biopharma (NASDAQ:IMMX) last released its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). Sell-side analysts anticipate that Immix Biopharma will post -0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immix Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in Immix Biopharma by 5.6% during the third quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock valued at $224,000 after acquiring an additional 7,954 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in Immix Biopharma in the 4th quarter worth $63,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of Immix Biopharma during the 4th quarter valued at about $38,000. Institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.